Design Therapeutics Net Worth
Design Therapeutics Net Worth Breakdown | DSGN |
Design Therapeutics Net Worth Analysis
Design Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Design Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Design Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Design Therapeutics' net worth analysis. One common approach is to calculate Design Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Design Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Design Therapeutics' net worth. This approach calculates the present value of Design Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Design Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Design Therapeutics' net worth. This involves comparing Design Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Design Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Design Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Design Therapeutics' net worth research are outlined below:
| Design Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (49.59 M) with loss before overhead, payroll, taxes, and interest of (49.93 M). | |
| Design Therapeutics currently holds about 359.38 M in cash with (43.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Design Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: What drives Design Therapeutics Inc. stock price - Overwhelming financial success - Jammu Links News |
Design Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Design Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Design Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 12th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Design Therapeutics Target Price Consensus
Design target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Design Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 3 | Buy |
Most Design analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Design stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Design Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationDesign Therapeutics Target Price Projection
Design Therapeutics' current and average target prices are 3.98 and 7.33, respectively. The current price of Design Therapeutics is the price at which Design Therapeutics is currently trading. On the other hand, Design Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Design Therapeutics Market Quote on 19th of July 2025
Target Price
Analyst Consensus On Design Therapeutics Target Price
Know Design Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Design Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Design Therapeutics backward and forwards among themselves. Design Therapeutics' institutional investor refers to the entity that pools money to purchase Design Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Kynam Capital Management, Lp | 2025-03-31 | 904 K | Geode Capital Management, Llc | 2025-03-31 | 775.5 K | State Street Corp | 2025-03-31 | 714.1 K | Woodline Partners Lp | 2025-03-31 | 645.7 K | Acadian Asset Management Llc | 2025-03-31 | 631 K | Mpm Oncology Impact Management Lp | 2025-03-31 | 562.9 K | D. E. Shaw & Co Lp | 2025-03-31 | 395.3 K | Northern Trust Corp | 2025-03-31 | 373.7 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 288.6 K | Sr One Capital Management, Lp | 2025-03-31 | 6.5 M | Logos Global Management Lp | 2025-03-31 | 4.2 M |
Follow Design Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 228.21 M.Market Cap |
|
Project Design Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.20) | (0.21) | |
| Return On Capital Employed | (0.26) | (0.24) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.20) | (0.19) |
When accessing Design Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Design Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Design Therapeutics' profitability and make more informed investment decisions.
Evaluate Design Therapeutics' management efficiency
Design Therapeutics has return on total asset (ROA) of (0.1656) % which means that it has lost $0.1656 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2259) %, meaning that it created substantial loss on money invested by shareholders. Design Therapeutics' management efficiency ratios could be used to measure how well Design Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of July 2025, Return On Tangible Assets is likely to drop to -0.21. In addition to that, Return On Capital Employed is likely to grow to -0.24. At this time, Design Therapeutics' Other Current Assets are very stable compared to the past year. As of the 19th of July 2025, Asset Turnover is likely to grow to 0.000007, while Total Assets are likely to drop about 240.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.28 | 3.05 | |
| Tangible Book Value Per Share | 4.28 | 3.05 | |
| Enterprise Value Over EBITDA | (6.71) | (7.05) | |
| Price Book Value Ratio | 1.44 | 1.51 | |
| Enterprise Value Multiple | (6.71) | (7.05) | |
| Price Fair Value | 1.44 | 1.51 | |
| Enterprise Value | 328.9 M | 369.6 M |
At Design Therapeutics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Design Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Design Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Design Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Design Therapeutics time-series forecasting models is one of many Design Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Design Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Design Therapeutics Earnings per Share Projection vs Actual
Design Therapeutics Corporate Management
| Jim Kerr | Chief Development | Profile | |
| Sean Jeffries | Chief Officer | Profile | |
| Doane Chilcoat | Chief Officer | Profile | |
| Elizabeth Gordon | Senior Affairs | Profile | |
| Mustapha Parekh | General Counsel | Profile | |
| MD FACC | Consulting Officer | Profile | |
| Dawn Giangiulio | Controller | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Design Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Design Therapeutics. If investors know Design will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Design Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Design Therapeutics is measured differently than its book value, which is the value of Design that is recorded on the company's balance sheet. Investors also form their own opinion of Design Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Design Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Design Therapeutics' market value can be influenced by many factors that don't directly affect Design Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Design Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Design Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Design Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.